Myovant Sciences Ltd Stock News

Wall Street analysts expect Myovant Sciences Ltd (NYSE:MYOV) to announce ($0.79) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Myovant S

The results were consistent with a pair of shorter studies of the combination treatment.

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Myovant Sciences (MYOV) and Aquestive Therapeutics (AQST)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Myovant Sciences ( MYOV – Research Report ) and Aquestive Therapeutics ( AQST – Research Report ) w

vTv Therapeutics (NASDAQ:VTVT) +80% on positive TTP399 data.Taubman Centers (NYSE:TCO) +52% on being acquired by Simon Property Group.Edgewell Personal Care (NYSE:EPC) +21% after Q4 results.Mereo B

Myovant Sciences (NYSE:MYOV) perks up 11% premarket on modest volume in reaction to positive results from a Phase 3 open-label extension study, LIBERTY, evaluating once-daily oral relugolix, combine

Myovant Sciences expects to report results from SPIRIT 2 in 1Q20 MYOV

Myovant Sciences expects to submit NDA for relugolix tablet in 2Q20 MYOV

Myovant Sciences reports Q4 EPS (96c), consensus (82c) MYOV

- 96.7% response rate in Phase 3 HERO study support submission of New Drug Application (NDA) for relugolix monotherapy tablet for advanced prostate cancer in the second quarter.

- 96.7% response rate in Phase 3 HERO study support submission of New Drug Application (NDA) for relugolix monotherapy tablet for advanced prostate cancer...

Myovant Sciences (MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that the Phase 3 LIBERTY open-label extension study of

Citigroup started coverage on shares of Myovant Sciences (NYSE:MYOV) in a research note issued to investors on Sunday morning, BenzingaRatingsTable reports. The brokerage issued a neutral rating and a

Q BioMed (OTCMKTS:QBIO) and Myovant Sciences (NYSE:MYOV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their ris

Relugolix combination regimen is targeting an underserved opportunity in uterine fibroids indication. Relugolix monotherapy can prove to be a game changer in an